Metal toxicity concern with metal hip devices
RATES of revision surgery for two recalled hip replacement devices are rising in Australia, as worry about metal toxicity is adding to concerns, surgeons say.
The rate of corrective surgery for the Articular Surface Replacement (ASR) XL Acetabular Hip System is 3.5 times the rate of other devices, affecting 13.5% of patients at six years.
The revision rate for the ASR Hip Resurfacing System, a lesser procedure, is now almost 2.5 times that of equivalent devices, at 11.1% of patients at six years, the Australian Orthopaedic Association (AOA) says.
A total of 5577 Australians have received the ASR device, made by Johnson & Johnson subsidiary DePuy, with 103 resurfacing and 329 total hip replacement patients having follow-up operations so far. DePuy is paying patients’ revision-related expenses up to 2015.
The new figures follow UK-based reports last month indicating a revision rate of 21% at four years